VISEN Pharmaceuticals

02561

Company Profile

  • Business description

    VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.

  • Contact

    69 Jiuzhang Road
    Suite 3-108, Floor 3, Building B
    Hengtai Lixiang Chuangxin Tower
    Suzhou
    CHN

    http://www.visenpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    52

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,741.9026.70-0.30%
CAC 407,804.8714.600.19%
DAX 4024,304.4619.12-0.08%
Dow JONES (US)42,762.87443.131.05%
FTSE 1008,837.9126.870.30%
HKSE23,792.54114.43-0.48%
NASDAQ19,529.95231.511.20%
Nikkei 22537,741.61187.120.50%
NZX 50 Index12,563.4813.67-0.11%
S&P 5006,000.3661.061.03%
S&P/ASX 2008,515.7023.20-0.27%
SSE Composite Index3,385.361.260.04%

Market Movers